Most Read

The companies will advance drug discovery programs by gaining insights into the polypharmacological profiles of small molecules, while further evolving Cyclica’s integrated network of enabling technologies. Through a

This approval is an important achievement for the company and most importantly, represents major progress for patients and physicians. Octapharma board member Olaf Walter said: “The development of

This second part of the Phase 1a study will enroll six healthy subjects per group, with a primary objective to assess safety and tolerability and a secondary objective

A total of 186 patients have been enrolled into the study, surpassing the Company’s initial target of 174 patients. The increased enrolment numbers followed high engagement from study

Tessa Therapeutics (Tessa), an international clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for cancer, is a leading developer of personalized T cell therapies for solid tumors,

This marks the first approval of a long-acting treatment for opioid dependence in the EU. London’s King’s College National Addiction Centre director professor Sir John Strang, said: “Patients

The research collaboration brings together Evotec’s leading induced pluripotent stem cell (iPSC) platform and broad drug discovery capabilities with Immuneering’s unique artificial intelligence-driven drug discovery platform to accelerate

The EC’s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance. Specifically, in relation to the future potential overlap

LEO Pharma research vice president Thorsten Thormann said: “We are very excited about the partnership with PellePharm, who are pioneers in Gorlin Syndrome and experts in rare skin